Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 38,070,452
  • Shares Outstanding, K 105,470
  • Annual Sales, $ 4,860 M
  • Annual Income, $ 896 M
  • 36-Month Beta 1.44
  • Price/Sales 8.03
  • Price/Cash Flow 36.67
  • Price/Book 8.78

Price Performance

See More
Period Period Low Period High Performance
1-Month
340.09 +6.14%
on 01/26/17
384.58 -6.14%
on 02/15/17
+6.60 (+1.86%)
since 01/23/17
3-Month
340.09 +6.14%
on 01/26/17
402.34 -10.28%
on 11/25/16
-41.45 (-10.30%)
since 11/23/16
52-Week
325.35 +10.95%
on 11/04/16
452.96 -20.31%
on 11/14/16
-25.87 (-6.69%)
since 02/23/16

Most Recent Stories

More News
Amgen's Repatha CVOT Results Are Potential Game-Changer for Lipid-Lowering Treatment

In its latest Cardiology Report, BioPharm Insight (BPI) reported that Amgen's Repatha Phase III FOURIER trial will be deemed successful by experts if it shows a 35% reduction in major...

SAN : 5.40 (+0.19%)
MDCO : 51.84 (-0.73%)
MRK : 65.85 (+0.86%)
ALNY : 46.25 (+0.65%)
ROG : 85.46 (-4.93%)
AMGN : 174.01 (+0.81%)
PFE : 34.06 (+1.40%)
LLY : 82.55 (+1.83%)
REGN : 360.96 (-2.50%)
NOVN : 4.92 (-6.46%)
MSB : 15.40 (-2.53%)
CAPR : 2.94 (-5.77%)
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.

AGIO : 47.40 (-3.25%)
RARE : 76.88 (-1.66%)
ZTS : 53.58 (+0.37%)
GILD : 69.37 (+0.78%)
REGN : 360.96 (-2.50%)
GSK : 41.49 (+1.12%)
SNY : 42.51 (-0.02%)
ALXN : 130.44 (-0.30%)
Amgen Looking to Broaden Leukemia Drug Blincyto's Label

Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.

CELG : 119.46 (+0.16%)
REGN : 360.96 (-2.50%)
AMGN : 174.01 (+0.81%)
SNY : 42.51 (-0.02%)
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

CELG : 119.46 (+0.16%)
INCY : 121.95 (+0.49%)
GILD : 69.37 (+0.78%)
ACOR : 25.00 (-0.99%)
SGEN : 63.07 (-2.34%)
REGN : 360.96 (-2.50%)
BIIB : 284.75 (-1.00%)
Regeneron Announces Upcoming 2017 Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:

REGN : 360.96 (-2.50%)
Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial

Upcoming AWS Coverage on Regeneron Pharmaceuticals Post-Earnings Results

ACOR : 25.00 (-0.99%)
REGN : 360.96 (-2.50%)
Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak

Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.

BAYRY : 111.3750 (-2.17%)
REGN : 360.96 (-2.50%)
AMGN : 174.01 (+0.81%)
SNY : 42.51 (-0.02%)
Regeneron (REGN) Q4 Earnings Misses Estimates

Regeneron???s fourth-quarter 2016 earnings missed expectations

REGN : 360.96 (-2.50%)
Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

REGN : 360.96 (-2.50%)
AMGN : 174.01 (+0.81%)
GSK : 41.49 (+1.12%)
SNY : 42.51 (-0.02%)
Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced today that the United States Court of Appeals for the Federal Circuit has stayed (suspended) the permanent injunction for Praluent®...

SAN : 5.40 (+0.19%)
REGN : 360.96 (-2.50%)
SNY : 42.51 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Support & Resistance

2nd Resistance Point 377.13
1st Resistance Point 369.05
Last Price 360.96
1st Support Level 355.05
2nd Support Level 349.13

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.